Phenotypic expression of 5-phosphoribosyl 1-pyrophosphate (PRPP) synthetase superactivity was examined in lymphoblast lines derived from six unrelated male patients. Fibroblasts 
Introduction
Superactivity of 5-phosphoribosyl 1-pyrophosphate (PRPP)' synthetase (EC 2.7.6.1), the enzyme catalyzing synthesis of the purine regulatory intermediate PRPP from ATP and ribose-5-phosphate (ribose-5-P) (1) , is an inherited disorder in which excessive enzyme activity is associated with uric acid overproduction and gout (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Erythrocytes and cultured fibroblasts from affected individuals show increases in PRPP concentration and generation as well as excessive rates of PRPP-dependent purine synthetic reactions (4) (5) (6) (7) (8) (13) (14) (15) . Increased rates of purine synthesis de novo have been shown both in affected males in vivo (2-4, 6-8, 10, 11, 16) and in their fibroblasts in vitro (3-5, 7, 11, 14, 15) . Uric acid overproduction in individuals with PRPP synthetase superactivity seems to result from increased PRPP availability with consequent acceleration of purine nucleotide synthesis. (14, 17) .
Among the heterogeneous kinetic defects underlying PRPP synthetase superactivity are: (a) catalytic defects due to increased maximal reaction velocity (6-8, 11, 18) ; (b) regulatory defects due to diminished responsiveness to purine nucleotide inhibitors of enzyme activity ( 14, 19) ; (c) substrate binding defects resulting in increased affinity for ribose-5-P (4); and (d) combined catalytic and regulatory defects (5) . Studies of superactive enzymes in each of these classes (4-8, 14, 18, 19) have provided evidence for structural alteration underlying superactivity. Furthermore, enzyme superactivity is transmitted as an X chromosome-linked trait (20, 21) , and the structural gene for the single PRPP synthetase subunit (22) has been localized to the long arm of the X chromosome (23) . Thus, even though demonstration of an altered primary structure of the enzyme protein has not, to date, been achieved for any superactive variant, structural gene mutation as the basis of enzyme superactivity is strongly suggested.
We have studied expression of PRPP synthetase superactivity in lymphoblast lines derived from peripheral blood B lymphocytes of affected male patients and have found that regulatory and substrate binding defects in PRPP synthetase are expressed in lymphoblast lines but catalytic defects are not. Absence of expression of this class of defects in lymphoblasts seems to be selective and is accompanied by absence in the cells of metabolic properties and in the enzyme of physical and immunochemical properties which in fibroblasts and erythrocytes distinguish superactive variant and normal phenotypes.
Laboratories (Grand Island, NY), and fetal bovine serum was a product of KC Biological Co. (Lenexa, KS). (Where appropriate, serum was dialyzed for 5 d at 4VC agairnst 20 vol 0.9% NaCI with daily changes of dialysate before filtration through a 0.2-gm Millipore filter.) Ficoll-Paque and Sephadex G-25 were purchased from Pharmacia Fine Chemicals (Piscataway, NJ); phytohemagglutinin M/P (PHA) was (5) . In the sixth patient (B.P.), the only kinetic abnormality is a substrate (ribose-5-P) binding defect (4) . Lymphoblast lines established from three individuals (C.L., K.C., and L.S.) with normal purine metabolism served as controls. C.L. and K.C. were entirely healthy at the time of initiation of the lymphoblast line, while lymphocytes from L.S. were cultured during an episode of infectious mononucleosis. All six patients served as donors of skin biopsy material for initiation of fibroblast cultures; fibroblast cultures derived from the skin of four normal individuals served as controls in the respective fibroblast studies.
Cell cultures. Lymphoblast lines were initiated from mononuclear cells isolated from 10 to 25 ml of fresh venous blood by centrifugation through Ficoll-Paque (24) . Cells were washed three times in RPMI 1640 medium supplemented with 2 mM L-glutamine, 15% fetal bovine serum, 50 U/ml penicillin, and 50 ,g/ml streptomycin (medium A) and were counted on a hemocytometer before resuspension in medium A at a density of 1.2 X 106 cells/ml. Portions ofthe cell suspensions (5 ml each) from patients T.B., M.C., A.D., and S.M. and from controls C.L. and K.C. were transferred to each ofseveral 25-cm2 Falcon flasks, also received 1 ml of medium A containing 100,000 U of B95-8 EB virus. After a 1-h incubation in a water bath at 37°C, cultures were incubated at 37°C in a humidified atmosphere of 5% CO2 in air and, thereafter, were treated as previously described (25) . Upon establishment of cultures, the fetal bovine serum concentration in the medium was reduced to 10% (medium B). Cultures were propagated in medium B at cell densities between 0.25 and 1.5 X 106/ml in 75 cm2 Falcon flasks containing no more than 60 ml per flask.
Four additional lymphoblast lines, two from affected patients (T.B. and B.P.) and two from normal individuals (K.C. and L.S.), were established after addition of rehydrated PHA (0.1 ml) (26) to 5-ml portions of the cell suspensions prepared in medium A, as described above. Although not exposed to exogenous EB virus, these cultures were otherwise treated and propagated as above. Lymphoblasts from patient N.B. (10) were provided by Dr. H. Anne Simmonds, Guy's Hospital, London, England.
Fibroblast cultures were initiated from skin biopsy specimens and were propagated in monolayer as previously described (27) . The growth medium was Eagle's minimal essential medium containing 2 mM Lglutamine, 10% fetal bovine serum, nonessential amino acids, penicillin (50 U/ml), and streptomycin (50 ,g/ml).
Preparation ofcell extracts. Lymphoblasts in log phase growth were resuspended in their medium, and, after cell density was determined, an appropriate volume of cell suspension was centrifuged at 800 g for 5 min. The cell pellet was washed three times in calcium-free DPBS, and cells were resuspended at an appropriate density (usually either 2 X 107 cells/ml or 1.5 X 108 cells/ml) in an extraction buffer at pH 7.4 containing 2 mM sodium inorganic phosphate (Pi), 1 mM dithiothreitol, and 1 mM EDTA. The cell suspension was then frozen in liquid nitrogen and either stored at -70'C or immediately subjected to further extract preparation and PRPP synthetase assay as described below.
On the day of enzyme assay, cell suspensions were thawed and subjected to two additional cycles offreezing in liquid nitrogen and thawing. Extracts were then centrifuged at 48,000 g for 20 min at 4VC. The supernatant layer (crude extract) was alternatively: dialyzed at 4VC for 120 min against 200 vol of extraction buffer before assay (dialyzed extract); or chromatographed on Sephadex G-25 (5) in extraction buffer at 4VC, and the material eluted at the excluded volume of the column (chromatographed extract) was assayed. On several occasions, lymphoblast PRPP synthetases were partially purified (10-fold to 30-fold) by treatment of crude extracts of -5 to 8 X I0O cells as previously described (5) .
Fibroblasts, harvested from subconfluent monolayers by treatment with trypsin and EDTA (5), were washed three times in DPBS, resuspended at densities ranging from 1 to 6 X 107 cells/ml, and extracted, dialyzed, and assayed for PRPP synthetase activity as described for lymphoblasts. Dialyzed extracts of peripheral blood mononuclear cells were prepared as described above after a portion of the mononuclear cells isolated from the Ficoll-Paque gradient were washed three times in DPBS. On one occasion, a previously described procedure (28) was applied to four blood mononuclear cell populations (one patient, three control), by which the resulting cell preparations were enriched to between 50 and 62% B lymphocytes before extract preparation.
Measurement ofPRPP synthetase activities. Activities of PRPP synthetase in cell extracts were determined by a modification (5) ofthe twostep assay procedure of Hershko et al. (29) . For all lymphoblast lines and fibroblast strains studied, maximal velocities ofthe PRPP synthetase reaction were measured at eight or more Pi concentrations ranging from 0.2 to 32.2 mM. Kinetic constants of lymphoblast PRPP synthetases were determined at 1.0 mM Pi as previously described (5): dissociation constants (KD) for substrates and Mg"2; and responses to purine nucleotide feedback inhibitors (10.5). Inhibitors studied were ADP, guanosine diphosphate (GDP), and 6-methylthioinosine (6-methylmercaptopurine ribonucleoside; MeSno) monophosphate (5, 30). The latter compound was synthesized, purified, and characterized as previously described (30).
Measurements ofPRPP and purine nucleotide metabolism in lymphoblasts. Lymphoblast PRPP concentrations were determined as described by Hershfield and Seegmiller (31) . In lymphoblasts harvested during log phase growth and resuspended in medium B containing 10% dialyzed bovine serum (medium C), rates of PRPP generation were calculated (5, 15) from simultaneously determined values for PRPP concentrations and rates of incorporation of ['4C]adenine into intracellular purine compounds (32, 33) .
To estimate rates of purine synthesis de novo in lymphoblasts, rates of incorporation of ['4C]formate either into the pathway intermediate formylglycinamide ribotide (FGAR) in the presence of the glutamine antagonist azaserine (27, 34, 35) or into intracellular purines and purines excreted into the incubation medium (31, 36) were determined. Cultures incubated overnight in medium C were centrifuged at 800 g for 5 min, and cells were resuspended in medium C lacking glutamine. Cell suspensions containing 2 X 106 lymphoblasts in 425 Ml ofthe above medium supplemented with 4 mM glycine with or without 0.1 mM azaserine were then prepared; each suspension was exposed to 5% CO2 in air, and tubes were sealed and incubated in a water bath-shaker at 37°C for 15 min. ['4C]Formate (25 uCi ; final concentration, 1 mM) and glutamine (final concentration, 10 mM) were then added to each cell suspension in 75 ,l of medium C, and incubation was continued for 1 h before centrifugation of the cell suspensions at 800 g for 5 min. Supernatant layers were removed and, where appropriate, saved. Cell pellets were rapidly washed four times with medium C. For cells incubated in the presence of azaserine, FGAR was extracted from cell pellets with 80% ethanol, separated from other label-containing compounds, and counted (35) . In the case of suspensions incubated in the absence of azaserine, label in intracellular purines was measured after thin layer chromatographic analysis (33) of the supernatant layers of neutralized perchloric acid-treated extracts, and radioactivity in purines excreted into the medium was measured after precipitation of purine compounds with silver nitrate as previously described (36, 37) . On two occasions, the above technique was modified (37) to utilize cell suspensions of20 ml containing 20 X 106 cells, which were incubated with ['4C]formate (10 ACi; final concentration, 10 MM) for 2 h at 370C before separation of cells and medium for determination of radioactivity in purine compounds.
Other methods. Lymphoblast content of PRPP synthetase was measured by a specific radioassay for immunoreactive enzyme (CRM) previously described in detail (38) . In each study, a standard line relating displacement of '25I-PRPP synthetase from rabbit antibody to the purified erythrocyte enzyme by a series of concentrations of unlabeled purified erythrocyte PRPP synthetase was generated. Displacement of labeled enzyme by multiple dilutions of dialyzed extracts of each lymphoblast line was tested in duplicate over a three-to fourfold range of labeled enzyme displacement on at least two separate occasions. Slopes of lines relating labeled enzyme displacement by purified erythrocyte PRPP synthetase and by dialyzed lymphoblast extracts agreed to within 3%, indicating that enzymes from each extract and from normal erythrocytes had similar affinities for the antibody. Enzyme absolute specific activity (activity per unit enzyme protein) was calculated from the results of radioimmunoassay and enzyme activity determinations carried out in parallel in identical extracts. All determinations of protein concentrations were carried out by the method of Lowry et al. (39) , using bovine serum albumin as standard.
Electrophoresis ofcrude lymphoblast and fibroblast extracts was carried out on cellulose acetate gel strips in three different buffer solutions at pH 8.5 as previously described (18, 21, 40) . Electrophoretic migration of PRPP synthetase was examined with an activity stain dependent upon reversal of the usual PRPP synthetase reaction (40) . Staining in the presence and absence of PRPP assured specific identification of the enzyme. Thermal inactivation of lymphoblast and fibroblast PRPP synthetases was studied at 57°C as described (18) . The major histocompatibility antigens (HLA-A and HLA-B) on fibroblasts and lymphoblasts derived from patients T.B., M.C., and A.D. were determined by the Tissue Typing Laboratory of the University of Illinois Medical Center, Chicago, utilizing a complement-dependent cytotoxicity assay (41) .
Results
Characteristics oflymphoblast cultures. Cells derived from normal individuals and patients did not differ in the time required for outgrowth of lymphoblasts after EB virus stimulation (2-6 wk) or PHA exposure (6-9 wk) ofblood mononuclear cells. Log phase doubling times for lymphoblast lines ranged from 28 to 43 h, and periodic variations in the doubling times of individual cultures were again noted (42). The comparisons described below among cell lines were made utilizing cultures with doubling times differing by no more than 3 h. Cell lines were propagated from both PHA-treated and EB virus-stimulated lymphocytes of one normal individual (K.C.) and one patient (T.B.). Lectin-treated and virus-treated cultures derived from the same persons were indistinguishable with regard to biochemical and physiological characteristics. Consequently, the studies presented below include data obtained from both lectin-stimulated and virus-stimulated cultures. The HLA-A and HLA-B antigens (four specificities in each case) expressed by the lymphoblasts from each patient tested were identical to those expressed by the fibroblasts from the respective patient, assuring that the cultures of the different cells were derived from the same patient source.
Characteristics ofPRPP synthetase activities in lymphoblasts. Table II . No significant differences in PRPP concentrations or generation were detected between normal lymphoblast lines and lines derived from patients with catalytically altered fibroblast PRPP synthetases. In contrast, PRPP concentrations and generation were increased in lymphoblasts from patients S.M., N.B., and B.P. Similarly, rates of purine synthesis de novo were increased only in lymphoblasts from these patients (Table II) . Lymphoblast lines bearing regulatory and substrate binding defects in PRPP synthetase excreted an in- (31) . Incorporation of ['4CJadenine into purine compounds (5, 32, 33) and incorporation of labeled formate into FGAR (35) and into total purines (31, 36, 37) were measured as described previously and in Methods. PRPP generation was calculated by the formula described (15) , which takes into account incorporation of ['4C]adenine and PRPP concentrations at each of several incubation times as well as the concentration of PRPP at zero min. In the determinations of purine synthesis, the proportion of total labeled purines detected in the medium (last column) agreed within -5% for each cell line by the two procedures employed (36, 37 Properties of lymphoblast PRPP synthetases. The uniform and apparently specific absence of phenotypic expression of catalytic superactivity in lymphoblasts suggested that PRPP synthetases in at least some lymphoblast lines might differ substantially in amounts, absolute specific activities, and/or additional properties relative to the respective enzymes previously studied in detail in erythrocytes and fibroblasts. Certain immunochemical and physical properties of lymphoblast PRPP synthetases were, therefore, examined.
Among six normal-derived and patient-derived lymphoblast lines, PRPP synthetase CRM differed by <20% (Table III) . Absolute specific activities of PRPP synthetase (Table III) were very similar for all lymphoblast lines tested and were in the range of values for PRPP synthetase absolute specific activities measured in erythrocytes and fibroblasts from normal individuals (38) .
In additional studies, aberrant electrophoresis and thermal stability properties of the enzyme, previously associated with phenotypic expression of some catalytic defects in fibroblasts (18, 21 ; and Becker, M. A., et al., manuscript submitted for publication), were sought in lymphoblasts. Cellulose acetate gel electrophoresis studies of fibroblast extracts (21, 41) showed reduced electrophoretic mobilities of PRPP synthetases from two patients (T.B. and A.D.) with catalytic overactivity (Fig. 2) (25, 31, 46, (48) (49) (50) (51) , adenosine kinase (46, 47) , and adenine phosphoribosyltransferase (47 14, 15) . In contrast, neither increased enzyme maximal reaction velocity nor abnormalities of PRPP and purine nucleotide synthesis were demonstrable in lymphoblasts derived from three patients with isolated catalytic superactivity of erythrocyte and fibroblast PRPP synthetases. PRPP synthetase in lymphoblasts from these patients also showed immunochemical and physical properties indistinguishable from those of the normal lymphoblast enzyme, in some cases failing to confirm differences in electrophoresis and thermal stability properties observed in fibroblast strains from the respective patients (18, 21 ; and Becker, M. A., et al., manuscript submitted for publication). In lymphoblasts from these individuals, then, no evidence for phenotypic expression of enzyme superactivity was detected. Between the extremes of full expression and nonexpression, an intermediate case was encountered for patient S.M., whose fibroblast enzyme is altered in both catalytic and regulatory properties (5) and whose lymphoblasts showed a feedback resistant enzyme and excessive rates of PRPP and purine synthesis unaccompanied by increased enzyme maximal reaction velocity. Thus, catalytically superactive PRPP synthetase was unexpressed in lymphoblasts from all four patients in whom catalytic defects in the fibroblast enzyme had been established (4, 5; and Becker, M. A., et al., manuscript submitted for publication), even in the setting of a co-existing regulatory defect which was expressed.
On the basis of these findings, it seems likely that the reliability of lymphoblast lines for studies of the genetic bases of PRPP synthetase superactivity may well be limited to cell lines in which kinetic abnormalities in enzyme activity and evidence for alteration in PRPP and purine nucleotide synthesis are identifiable. The absence of catalytic defects in lymphoblast lines derived from patients with such defects in fibroblasts raises questions about the nature of this class of inherited PRPP synthetase superactivity and the determinants of its expression. Among potential explanations for absence of expression of catalytic superactivity, the results ofimmunochemical studies (Table  III) made unlikely the possibility that differences in concentrations of PRPP synthetases among cell lines were obscuring differences in absolute specific activities of individual forms of the enzyme. These studies also provided evidence against selective activation of normal PRPP synthetase as an explanation for comparable catalytic activity in normal-derived and patient-derived lymphoblasts. These and additional studies of physical properties of the enzymes favored the suggestion that lymphoblast PRPP synthetases from patients with catalytic superactivity are structurally different from their enzyme counterparts in fibroblasts and erythrocytes. Moreover, since increased PRPP synthetase activities were found in extracts of freshly isolated peripheral blood mononuclear cells from the two patients with catalytic superactivity tested, expression of catalytic defects in B cells before transformation into lymphoblasts seems likely. Thus, the selective loss of expression of catalytic superactivity in lymphoblasts appears to reflect an event occurring in (or missing from) transformed lymphocytes, which specifically effects the structure of the enzyme. At which level between the structural gene coding for PRPP synthetase and the active enzyme product such alteration is effected is uncertain.
We believe that the data presented make unlikely several possible explanations for absence of expression of catalytic superactivity in lymphoblasts. These include spontaneous reversion to normal ofall and only the genetic defects underlying catalytic superactivity and the existence of a structural gene for lymphoblast PRPP synthetase different from that coding for the erythrocyte and fibroblast forms of the enzyme. Similarly, absolute specific activities of lymphoblast PRPP synthetases provide no support for a model, suggested by the work of Martin and colleagues (56, 57), in which catalytically superactive PRPP synthetase is an induced and activated form in untransformed cells, with loss ofthe catalytically superactive phenotype representing conversion of normal enzyme to the induced and activated form during lymphocyte transformation.
Posttranslational modification of the enzyme is another mechanism by which the structure and activity of lymphoblast PRPP synthetase may differ from that of the enzyme in other cells. If, for example, expression ofcatalytic superactivity requires a posttranslational alteration unique to these genetically altered forms of the enzyme, an activity mediating this modification may not be expressed in lymphoblasts. The possibility of such a mechanism must remain speculative in the absence ofevidence to affirm or deny its operation. Nor is it possible to exclude with certainty an alternative hypothesis in which the primary genetic defect underlying catalytic superactivity resides in the gene coding for a posttranslational modifier ofstructurally normal PRPP synthetase. Studies aimed at establishing the precise nature of inherited defects underlying PRPP synthetase superactivity and at evaluating the possibility of posttranslational modification of the enzyme will likely provide insight into the selective expression of enzyme superactivity in lymphoblasts.
